These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 10090162)

  • 1. Conversion of patients with rheumatoid arthritis from the conventional to a microemulsion formulation of cyclosporine: a double blind comparison to screen for differences in safety, efficacy, and pharmacokinetics.
    Anderson IF; Helve T; Hannonen P; Leirisalo-Repo M; Gilboe IM; Nissilä M; Keystone EC; Kraag GR; Bjørneboe O; Chalmers A; Dovland H; Mueller E; Richard F; Whatmough I; Schmidt AG; Kovarik JM
    J Rheumatol; 1999 Mar; 26(3):556-62. PubMed ID: 10090162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of conversion from stable Sandimmun maintenance treatment to Sandimmun Neoral in patients with rheumatoid arthritis.
    Flipo RM; Emery P; Scott DG; Situnayake RD; Prowse PJ; James DW; Cawley MI; Whatmough I; Schmidt AG
    J Rheumatol; 1998 Jul; 25(7):1263-9. PubMed ID: 9676754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of cyclosporin A pharmacokinetics of a new microemulsion formulation and standard oral preparation in patients with psoriasis.
    Erkko P; Granlund H; Nuutinen M; Reitamo S
    Br J Dermatol; 1997 Jan; 136(1):82-8. PubMed ID: 9039300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporine pharmacokinetics and variability from a microemulsion formulation--a multicenter investigation in kidney transplant patients.
    Kovarik JM; Mueller EA; van Bree JB; Flückiger SS; Lange H; Schmidt B; Boesken WH; Lison AE; Kutz K
    Transplantation; 1994 Sep; 58(6):658-63. PubMed ID: 7940685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microemulsion formulation of cyclosporin (Sandimmun Neoral) vs Sandimmun: comparative safety, tolerability and efficacy in severe active rheumatoid arthritis. On behalf of the OLR 302 Study Group.
    Yocum DE; Allard S; Cohen SB; Emery P; Flipo RM; Goobar J; Jayawardena S; Job-Deslandre C; Jubb RW; Krüger K; Lopes Vaz A; Manger B; Mur E; Nygaard H; Weiner SM; Rainer F; Sack MR; Schiff MH; Schnitzer TJ; Trigg LB; Whatmough I; Schmidt AG
    Rheumatology (Oxford); 2000 Feb; 39(2):156-64. PubMed ID: 10725065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy, tolerability and safety of cyclosporine for microemulsion in the treatment of active rheumatoid arthritis. Open study].
    Marcos JC; Maccagno A; Gutfraind E; Garsd A; Messina DO; Maldonado Cocco J; Battagliotti C; Onetti CM; Tate G; Venarotti HO; Grosman H; Díaz EA; Otero AB
    Medicina (B Aires); 2000; 60(4):435-40. PubMed ID: 11188947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine.
    van den Borne BE; Landewé RB; Goei The HS; Rietveld JH; Zwinderman AH; Bruyn GA; Breedveld FC; Dijkmans BA
    J Rheumatol; 1998 Aug; 25(8):1493-8. PubMed ID: 9712089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equivalence of cyclosporine blood level assays in patients receiving cyclosporine microemulsion or cyclosporine. The Sandoz Neoral Study Group N103.
    Pescovitz MD; Wong RL; Choc MG; Chang CT
    Clin Transplant; 1997 Oct; 11(5 Pt 1):442-5. PubMed ID: 9361938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
    Rau R; Sander O; van Riel P; van de Putte L; Hasler F; Zaug M; Kneer J; van der Auwera P; Stevens RM;
    J Rheumatol; 2003 Apr; 30(4):680-90. PubMed ID: 12672184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability.
    Zachariae H; Abrams B; Bleehen SS; Bräutigam M; Burrows D; Ettelt MJ; Fry L; Happle R; Haustein UF; Ganslandt J; Jung EG; Knop J; Kühne KH; Mellein B; Mørk NJ; Rogers S; Schmidt AG; Schopf RE; Sumner M; Taube KM; Weidinger G; Wurdel C; Zahn E
    Dermatology; 1998; 196(2):231-6. PubMed ID: 9568413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial.
    Lee EY; Lee EB; Park BJ; Lee CK; Yoo B; Lim MK; Shim SC; Sheen DH; Seo YI; Kim HA; Baek HJ; Song YW
    Clin Ther; 2006 Dec; 28(12):2052-60. PubMed ID: 17296461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of Neoral in rheumatoid arthritis.
    Cranney A; Tugwell P
    Rheum Dis Clin North Am; 1998 Aug; 24(3):479-88. PubMed ID: 9710882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative bioavailability of the microemulsion formulation of cyclosporine (Neoral) with a generic dispersion formulation (Cicloral) in young healthy male volunteers.
    Kees F; Bucher M; Schweda F; Gschaidmeier H; Burhenne J; Mikus G; Faerber L
    Ther Drug Monit; 2006 Jun; 28(3):312-20. PubMed ID: 16778713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Keystone EC; Schiff MH; Kremer JM; Kafka S; Lovy M; DeVries T; Burge DJ
    Arthritis Rheum; 2004 Feb; 50(2):353-63. PubMed ID: 14872476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function.
    Qazi YA; Forrest A; Tornatore K; Venuto RC
    Clin Transplant; 2006; 20(3):313-7. PubMed ID: 16824147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diclofenac combined with cyclosporine in treatment refractory rheumatoid arthritis: longitudinal safety assessment and evidence of a pharmacokinetic/dynamic interaction.
    Kovarik JM; Kurki P; Mueller E; Guerret M; Markert E; Alten R; Zeidler H; Genth-Stolzenburg S
    J Rheumatol; 1996 Dec; 23(12):2033-8. PubMed ID: 8970037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
    Nuki G; Bresnihan B; Bear MB; McCabe D;
    Arthritis Rheum; 2002 Nov; 46(11):2838-46. PubMed ID: 12428223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials.
    Pham B; Cranney A; Boers M; Verhoeven AC; Wells G; Tugwell P
    J Rheumatol; 1999 Mar; 26(3):712-6. PubMed ID: 10090188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine A in rheumatoid arthritis: randomized, placebo controlled dose finding study.
    Altman RD; Schiff M; Kopp EJ
    J Rheumatol; 1999 Oct; 26(10):2102-9. PubMed ID: 10529124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of CyA microemulsion formulation (Sandimmun Neoral) in stable renal transplant patients after 24 months of treatment. German Neoral Study Group.
    Offermann G; Korn A
    Transplant Proc; 1996 Aug; 28(4):2204-6. PubMed ID: 8769201
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.